Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ODAC to review Evista

Executive Summary

FDA's Oncology Drug Advisory Committee will review Lilly's Evista (raloxifene) for reduction in the risk of invasive breast cancer in postmenopausal women at high risk for breast cancer and those with osteoporosis July 24. Evista is approved for treatment and prevention of osteoporosis in postmenopausal women, which may help raloxifene gain ground in the cancer prevention market (1"The Pink Sheet" June 11, 2007, p. 14). GPC's satraplatin will also be discussed (2"The Pink Sheet" May 21, 2007, In Brief)...

You may also be interested in...

Lilly Evista Breast Cancer Market May Build On Osteo Acceptance

Physician experience in treating osteoporosis patients with Lilly's Evista (raloxifene) might improve the product's uptake for reducing the risk of breast cancer

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts